https://ir.avalotx.com/news-events-presentations/press-releases/rss en-us https://d1io3yog0oux5.cloudfront.net/_ea697aa916e28469528b0006da59afb9/avalotx/files/theme/images/logo-sm.png Equisolve Investor Relations Suite https://ir.avalotx.com/news-events-presentations/press-releases/detail/227/avalo-therapeutics-to-join-the-russell-2000-and-russell-3000-indexes Fri, 26 Jun 26 07:00:00 -0400 https://ir.avalotx.com/news-events-presentations/press-releases/detail/227/avalo-therapeutics-to-join-the-russell-2000-and-russell-3000-indexes https://ir.avalotx.com/news-events-presentations/press-releases/detail/226/avalo-therapeutics-appoints-ron-philip-to-board-of-directors Tue, 23 Jun 26 07:00:00 -0400 https://ir.avalotx.com/news-events-presentations/press-releases/detail/226/avalo-therapeutics-appoints-ron-philip-to-board-of-directors https://ir.avalotx.com/news-events-presentations/press-releases/detail/225/avalo-therapeutics-expands-pipeline-with-avtx-010-a-long-acting-next-generation-anti-il-1-antibody Tue, 16 Jun 26 07:00:00 -0400 https://ir.avalotx.com/news-events-presentations/press-releases/detail/225/avalo-therapeutics-expands-pipeline-with-avtx-010-a-long-acting-next-generation-anti-il-1-antibody https://ir.avalotx.com/news-events-presentations/press-releases/detail/224/avalo-therapeutics-announces-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635c4 Fri, 22 May 26 16:01:00 -0400 https://ir.avalotx.com/news-events-presentations/press-releases/detail/224/avalo-therapeutics-announces-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635c4 https://ir.avalotx.com/news-events-presentations/press-releases/detail/223/avalo-therapeutics-reports-first-quarter-2026-financial-results-and-recent-business-updates Wed, 13 May 26 07:00:00 -0400 https://ir.avalotx.com/news-events-presentations/press-releases/detail/223/avalo-therapeutics-reports-first-quarter-2026-financial-results-and-recent-business-updates https://ir.avalotx.com/news-events-presentations/press-releases/detail/222/avalo-therapeutics-announces-pricing-of-375-million-public-offering Tue, 05 May 26 23:33:00 -0400 https://ir.avalotx.com/news-events-presentations/press-releases/detail/222/avalo-therapeutics-announces-pricing-of-375-million-public-offering https://ir.avalotx.com/news-events-presentations/press-releases/detail/221/avalo-therapeutics-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants Tue, 05 May 26 16:05:00 -0400 https://ir.avalotx.com/news-events-presentations/press-releases/detail/221/avalo-therapeutics-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants https://ir.avalotx.com/news-events-presentations/press-releases/detail/220/avalo-therapeutics-achieves-positive-topline-results-in-phase-2-lotus-trial-of-abdakibart-avtx-009-in-moderate-to-severe-hidradenitis-suppurativa Tue, 05 May 26 16:01:00 -0400 https://ir.avalotx.com/news-events-presentations/press-releases/detail/220/avalo-therapeutics-achieves-positive-topline-results-in-phase-2-lotus-trial-of-abdakibart-avtx-009-in-moderate-to-severe-hidradenitis-suppurativa https://ir.avalotx.com/news-events-presentations/press-releases/detail/219/avalo-therapeutics-purchases-optional-milestone-buyout Tue, 28 Apr 26 07:00:00 -0400 https://ir.avalotx.com/news-events-presentations/press-releases/detail/219/avalo-therapeutics-purchases-optional-milestone-buyout https://ir.avalotx.com/news-events-presentations/press-releases/detail/218/avalo-therapeutics-reports-2025-financial-results-and-recent-business-updates Mon, 23 Mar 26 07:00:00 -0400 https://ir.avalotx.com/news-events-presentations/press-releases/detail/218/avalo-therapeutics-reports-2025-financial-results-and-recent-business-updates